Chemical structural formula and molecular formula analysis of DaliRasan

Daridorexant is one of the dual orexin receptor antagonists currently used clinically. Its chemical structure has been carefully optimized and designed to have both pharmacodynamic activity, brain penetration and metabolic stability. Its commonly used drug form is Daridorexant hydrochloride, which is mainly used in tablet formulations for the oral treatment of insomnia.

The chemical name is:(S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride. This naming system describes its molecular skeleton, chiral configuration and functional group distribution in detail, showing that the molecule has a high degree of structural complexity.

The molecular formula of Dalilaysan is C23H23ClN6O2·HCl, and its molecular weight is approximately 491.4 g/mol. Its core structure contains benzimidazole ring, triazole ring, pyrrolidine ring and other aromatic and heterocyclic systems. These structures give it good receptor binding ability and fat solubility, which is beneficial to crossing the blood-brain barrier and acting on orexin receptors in the central nervous system. In addition, substituents such as chlorinated aromatic rings, methyl and methoxy groups were introduced into the structure to optimize affinity, oral bioavailability and metabolic stability.

DaliRasen works through balanced antagonism ofOX1R and OX2R without biasing towards a single pathway, ensuring that it is more natural and stable in the process of regulating wakefulness and sleep. Its chiral configuration is the S-isomer. This configuration is the active form and is also a key control point in the synthesis process of drugs.

In drug synthesis and industrial production, the preparation process of Dalilaysan covers multi-step organic synthesis, involving chiral center control and the construction of polycyclic structures, and the technical barriers are relatively high. At present, the world is mainly synthesized by Idorsia with authorization. The structure information of related compounds can be found in PubChem, DrugBank and EMA registration data.

Reference materials:https://www.quviviq.com/